Novel strategies for cancer immunotherapy: counter-immunoediting therapy

por Liu, Shaochuan, Sun, Qian, Ren, Xiubao
Publicado 2023

PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival

por Liu, Shaochuan, Qin, Tingting, Jia, Yanan, Li, Kai
Publicado 2019

Immune‐independent acquired resistance to PD‐L1 antibody initiated by PD‐L1 upregulation via PI3K/AKT signaling can be reversed by anlotinib

por Gao, Yuan, Feng, Yingfang, Liu, Shaochuan, Zhang, Yan, Wang, Jing, Qin, Tingting, Chen, Peng, Li, Kai
Publicado 2023

Clinical importance of VEGFC and PD‐L1 co‐expression in lung adenocarcinoma patients

por Qin, Tingting, Xia, Junling, Liu, Shaochuan, Wang, Jing, Liu, Hailin, Zhang, Yan, Jia, Yanan, Li, Kai
Publicado 2020

anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells

por Liu, Shaochuan, Qin, Tingting, Liu, Zhujun, Wang, Jing, Jia, Yanan, Feng, Yingfang, Gao, Yuan, Li, Kai
Publicado 2020

Anlotinib suppresses lymphangiogenesis and lymphatic metastasis in lung adenocarcinoma through a process potentially involving VEGFR-3 signaling

por Qin, Tingting, Liu, Zhujun, Wang, Jing, Xia, Junling, Liu, Shaochuan, Jia, Yanan, Liu, Hailin, Li, Kai
Publicado 2020

Molecular subtypes based on CNVs related gene signatures identify candidate prognostic biomarkers in lung adenocarcinoma

por Li, Baihui, Huang, Ziqi, Yu, Wenwen, Liu, Shaochuan, Zhang, Jian, Wang, Qingqing, Wu, Lei, Kou, Fan, Yang, Lili
Publicado 2021

Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab

por Liu, Zhujun, Qin, Tingting, Yuan, Xiaohan, Yang, Jie, Shi, Wei, Zhang, Xiaoling, Jia, Yanan, Liu, Shaochuan, Wang, Jing, Li, Kai
Publicado 2022

CD4(+) T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer

por Liu, Shaochuan, Meng, Yuan, Liu, Liang, Lv, Yingge, Yu, Wenwen, Liu, Ting, Wang, Limei, Mu, Di, Zhou, Qiuru, Liu, Min, Ren, Yulin, Zhang, Dong, Li, Baihui, Sun, Qian, Ren, Xiubao
Publicado 2022